PCI Biotech: Capital increase registered and listing of new shares


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Reference is made to the previous announcements by PCI Biotech Holding ASA ("PCI Biotech" or the "Company") in respect of the fully underwritten rights issue of 7,000,000 new shares in the Company (the "Rights Issue").

The share capital increase pertaining to the Rights Issue, resolved by the extraordinary general meeting on 6 January 2015, has now been registered in the Norwegian Register of Business Enterprises, and the Rights Issue has thus been completed.

PCI Biotech's new share capital is NOK 44,179,170 divided by 14,726,390 shares, each with a nominal value of NOK 3.00 and each giving one vote at the Company's general meeting.

The new shares issued in the Rights Issue will be registered on the respective subscribers' VPS accounts and be tradable on the Oslo Stock Exchange from and including 12 February 2015.

DNB Markets and Fondsfinans are acting as Joint Bookrunners in connection with the Rights Issue. Advokatfirmaet Selmer DA is acting as the Company's legal advisor in connection with the Rights Issue.

Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 940 05 757

IMPORTANT NOTICE
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company. The Company's financial advisors are  acting exclusively  for  the  Company  and  no  one  else, and will not be responsible to anyone  other  than  the  Company for providing the protections afforded to their respective clients,  or for advice in  relation to the Rights Issue, the contents of this announcement or  any of  the matters  referred to herein. The Rights Issue and the distribution of this announcement and other information in connection with the Rights Issue may be restricted by law in certain jurisdictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about, and to observe, any such restrictions. This announcement may not be used for, or in connection with, and does not constitute, any offer of securities for sale in the United States or in any other jurisdiction.

The Rights Issue will not be made in any jurisdiction or in any circumstances in which such offer or solicitation would be unlawful. This announcement is not for distribution, directly or indirectly in or into any jurisdiction in which it is unlawful to make any such offer or solicitation to such person or where prior registration or approval is required for that purpose. No steps have been taken or will be taken relating to the Rights Issue in any jurisdiction outside of Norway in which such steps would be  required. Neither the publication and/or delivery of this announcement shall under any circumstances imply that there has been no change in the affairs of the Company or that the information contained herein is correct as of any date subsequent to the earlier of the date hereof and any earlier specified date with respect to such information.

This announcement is not for publication or distribution, directly or indirectly, in the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form  part  of  any  offer or solicitation to purchase or subscribe for securities in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. The shares to be sold in the Rights Issue have not been and will not be registered under the United States Securities  Act of 1933, as amended (the "US Securities  Act") or with any securities regulatory  authority of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or  to, or  for the  account of, U.S. persons  (as such  term is defined in Regulation  S under  the US  Securities Act), except pursuant to an effective registration statement under, or an exemption  from the registration requirements of, the US Securities Act. All offers and sales outside the United States will be made in reliance on Regulation S under the US Securities Act. There will be no public offer of securities in the United States This announcement  does  not  constitute  an  offering circular  or  prospectus  in connection with an offering of securities of the Company. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on  the basis of the  information contained in the prospectus made available by the Company only to qualified persons in certain jurisdictions where an offer may  be made (if  an offer is  made). This announcement does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities and cannot be relied  on for  any investment  contract or decision.
  

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
GlobeNewswire